Publications by authors named "S Dubucquoi"
Janus kinase (JAK) molecules are involved in important cellular activation pathways. Over the past decade, many targeted therapies have emerged, including the increasingly promising role of JAK inhibitors (JAKi) in the treatment of inflammatory and autoimmune diseases. The spectrum of use of these small molecules is increasingly broader.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers measured the prevalence of IgG anti-IgA in PID patients compared to healthy controls and found a low percentage of PID patients with these antibodies and hypersensitivity.
- * The study suggests that complement activation might be a more significant factor in hypersensitivity reactions to immunoglobulin preparations, rather than just the presence of IgG anti-IgA.
Article Synopsis
- - C5-blockers are currently the recommended treatment for complement-mediated hemolytic uremic syndrome (CM-HUS), but lack definitive testing often leads to plasma exchanges as the first treatment, despite limited evidence.
- - A study involving 7 patients treated without plasmapheresis showed that administering a C5-blocker called eculizumab promptly led to rapid hematological recovery and improved renal function for most patients.
- - The promising results suggest the need for further clinical trials to confirm this approach's effectiveness and safety while also addressing the high costs associated with C5-blocker therapies for broader use in adults with renal thrombotic microangiopathy (TMA).
Purpose: High throughput technologies have identified molecular patterns in colorectal cancer (CRC) cells, aiding in modeling responses to anti-cancer treatments. The different responses observed depend on the type of cancer, the tumour grade and the functional programme of the cancer cells. Recent studies suggest that the unfolded protein response (UPR), autophagy and apoptosis could be involved in treatment resistance mechanisms by interacting with the tumour microenvironment (TME).
View Article and Find Full Text PDFIntroduction: In systemic sclerosis (SSc), B-cells are activated and present in the skin and lung of patients where they can interact with fibroblasts. The precise impact and mechanisms of the interaction of B-cells and fibroblasts at the tissular level are poorly studied.
Objective: We investigated the impact and mechanisms of B-cell/fibroblast interactions in cocultures between B-cells from patients with SSc and 3-dimensional reconstituted healthy skin model including fibroblasts, keratinocytes and extracellular matrix.